Meridian Bioscience
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Meridian Bioscience's revenues will expand 16.3% and EPS will grow 29.4%.
The average estimate for revenue is $46.6 million. On the bottom line, the average EPS estimate is $0.22.
Revenue details
Last quarter, Meridian Bioscience tallied revenue of $47.4 million. GAAP reported sales were 16% higher than the prior-year quarter's $41.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, EPS came in at $0.23. GAAP EPS of $0.23 for Q2 were 28% higher than the prior-year quarter's $0.18 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 62.7%, 50 basis points worse than the prior-year quarter. Operating margin was 31.7%, 200 basis points better than the prior-year quarter. Net margin was 20.3%, 260 basis points better than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $182.5 million. The average EPS estimate is $0.85.
Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 469 members rating the stock outperform and 12 members rating it underperform. Among 110 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 107 give Meridian Bioscience a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is hold, with an average price target of $20.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Meridian Bioscience. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Meridian Bioscience to My Watchlist.